Xi`an Eastling Biotech Co., Ltd.
Diamond Supplier
- Diamond
Supplier - 1st
years
Diamond Supplier
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Lab/Research institutions
Tel: +86-156-91766041
Mobile:
Tel: +86-156-91766041
Fax:
URL: http://www.eastlingbiotech.com/
Province/state: Shaanxi
City: Xi'an city
Street: No. 201, Unit 4, Building 9, Hongqi Community, Tanjia Street, Weiyang District, Xi 'an, Shaanxi
MaxCard:
Contact Suppliers
CAS NO.19171-19-8
98%(500-1000)Kilogram98%(100-500)Metric Ton
| Molecular Formula | C13H11N3O4 |
| Molar Mass | 273.24 |
| Density | 1.570±0.06 g/cm3(Predicted) |
| Melting Point | 318.5 - 320.5° |
| Boling Point | 582.9±45.0 °C(Predicted) |
| Flash Point | 306.3°C |
| Solubility | DMSO:54 mg/mL (197.62 mM);Water :Insoluble;Ethanol :Insoluble mother liquor preservation: sub-packaging and freezing to avoid repeated freezing and thawing;-20 ℃,1 month;-80 ℃,6 |
| Vapor Presure | 1.41E-13mmHg at 25°C |
| Appearance | Light yellow to yellow solid |
| Color | yellow |
| Merck | 14,135 |
| pKa | 10.75±0.40(Predicted) |
| Storage Condition | 2-8°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
| Refractive Index | 1.691 |
| Use | This product is for scientific research only and shall not be used for other purposes. |
| In vitro study | Pomalidomide inhibits lipopolysaccharide (LPS)-stimulated release by TNF-alpha, with IC50 values of 13 nM and 25 nM for human PBMC and total human blood, respectively. Pomalidomide inhibited IL-2 of stimulated T regulatory cells with an IC50 of ~ 1 μm. Treatment of human peripheral blood T cells with 6.4 nM-10 μm Pomalidomide increased production by IL-2 and was more effective on the CD4 + subset than on the CD8 + subset. Pomalidoride significantly promoted IFN-γ by CC-5013, IL-2, and IL-5 over IL-10, and slightly promoted IFN-γ over CC-5013. Pomalidomide acts on Jurkat cells to enhance the AP-1 transcriptional activity induced by SEE and Raji cells, up to 4-fold at 1 μm, in a dose-dependent manner. Treatment of Raji cells with different concentrations of pomalido IDE (2.5-40 μg/mL) for 48 hours resulted in a significant decrease in cell proliferation and DNA synthesis by-40% compared to the control group. |
| In vivo study | Pomalidomide acts on SCID mice to enhance the anticancer effect of Rituximab on B- cell lymphoma. The combination of pomalidoxide and Rituximab resulted in an average life span of 74 days in mice and 58 days in mice treated with CC5013/Rituximab. NK cell depletion completely abolished the synergistic effect of pomalidoride and Rituximab, indicating that the increase in NK cells is a mechanism by which pomalidoride enhances the anticancer effect of Rituximab. |
| introduction | pomalidomide (Pomalidomide) is a newly listed third-generation immunomodulator (Immuno-modulatorydrug,IMiD), developed by Celgene, USA. it is a drug modified and synthesized on the basis of the chemical structure of the first-generation IMiD thalidomide, it can enhance the immune response mediated by T cells and natural killer cells, inhibit the production of pro-inflammatory cytokines of monocytes, and induce tumor cell apoptosis. It has attracted extensive attention in the treatment of various malignant tumors and immune diseases. |
| features | compared with the first and second generation IMiD, pomalidomide is relatively more pharmacological, less toxic and better tolerated by patients. its good anti-angiogenesis, anti-tumor and anti-inflammatory effects have been widely recognized in the pre-clinical studies of multiple myeloma (Multiplemyeloma,MM). |
| Use | The chemical name of pomalidomide is 4-amino-2-(2, 6-dioxo-piperidine-3-yl)-Isodihydroindol-1, 3-dione, is a thalidomide analog, an immunomodulator with anti-tumor activity. In vitro cytology tests, it can inhibit the proliferation of hematopoietic tumor cells and induce apoptosis. In addition, pomalidomide can inhibit the proliferation of lenalidomide-resistant multiple myeloma cell lines and induce tumor cell apoptosis in cooperation with dexamethasone. |
| biological activity | Pomalidomide inhibit LPS-induced TNF-alpha release with IC50 of 13 nM. |
| in vitro study | Pomalidomide inhibit lipopolysaccharide (LPS)-stimulated TNF-alpha release, IC50 is 13 nM and 25 nM respectively when acting on human PBMC and all human blood. Pomalidomide inhibit IL-2-stimulated T regulatory cells, IC50 is ~ 1 μM. 6.4 nM-10 μM Pomalidomide to treat human peripheral blood T cells to increase IL-2 yield. It is more effective on CD4 + subsets than CD8 + subsets. Pomalidomide significantly promotes IL-2, IL-5, and IL-10 than CC-5013, and slightly promotes IFN-γ than CC-5013. Pomalidomide acts on Jurkat cells to enhance the AP-1 transcription activity induced by SEE and Raji cells, with a maximum of 4-fold enhancement at 1 μM. This effect is dose-dependent. Treatment of Raji cells with different concentrations of Pomalidomide(2.5-40 μg/mL) for 48 hours resulted in a significant decrease in cell proliferation and DNA synthesis, which was ~ 40% lower than that of the control group. |
| In vivo studies | Pomalidomide act on SCID mice to enhance the anti-cancer effect of Rituximab on B- cell lymphoma. The average lifespan of rats with Pomalidomide and Rituximab was 74 days, and that of rats treated with CC5013/Rituximab was 58 days. When NK cells are exhausted, the synergistic effect of Pomalidomide and Rituximab is completely abolished, indicating that the increase of NK cells is a mechanism that Pomalidomide enhances Rituximab cancer. |
| feature | Pomalidomide are Thalidomide derivatives, and the effect is 10,000 times stronger than Thalidomide. |
| Preparation | is to use 3-nitrophthalic anhydride as the starting material and react with 3-amino-2, 6-piperidinedione, and the prepared product is reduced by Pd/C in a hydrogen environment to obtain the target compound pomalidomide. Although the steps of the reaction route are short, 3-nitrophthalic anhydride is an unstable raw material, which is easy to hydrolyze and deteriorate during transportation or storage, the quality of the raw material is not guaranteed, and the reaction process is an intermittent reaction system., The degree of continuity is low, hydrogen is a high-risk gas, and the safety of the production environment is low. |
CAS:
19171-19-8
MF:
C13H11N3O4
MW:
273.24
EINECS:
805-902-5
MDL No.:
MFCD12756407
Melting point:
318.5 - 320.5°
Boiling point:
582.9±45.0 °C(Predicted)
Density
1.570±0.06 g/cm3(Predicted)
storage temp.
2-8°C
solubility
DMSO: ≥14mg/mL
pka
10.75±0.40(Predicted)
form
powder
color
yellow
Merck
14,135
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
InChI
InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
InChIKey
UVSMNLNDYGZFPF-UHFFFAOYSA-N
SMILES
C1(=O)C2=C(C(N)=CC=C2)C(=O)N1C1CCC(=O)NC1=O
Xi'an Eastling biotech Co., Ltd. is dedicated to the research and development, production, and sales of natural plant extracts; With nearly 15 years of experience in identifying, researching, developing, and producing active ingredients for medicinal plants, we focus on providing innovative products and services to customers in industries such as pharmaceuticals, health food, and cosmetics.
Eastling Biotechnology has established a global direct harvesting system for plant raw materials, ensuring the high quality and authenticity of raw materials, while also protecting the continuity and diversity of plants; Having strong research and development capabilities, we can develop more effective and specialized plant active ingredients for the pharmaceutical, health food, and cosmetics industries; We have established an advanced quality control system, and the quality control of our products depends on advanced testing instruments and high-level technical experts. The effective combination of the two forms Eastling's ability to quickly and rigorously control product quality.
We have a production system that complies with Chinese GMP and American cGMP certifications, as well as advanced and optimized large-scale industrial production technology. In addition to producing specific products for Eastling Biotechnology, we also provide customized services to meet the characteristics and needs of different customers to produce customized products.
We believe that natural active ingredients are the foundation of our service to customers. Scientific and effective production technology is the foundation for us to provide customers with specialized products. We have the ability to serve customers in the pharmaceutical, health food, and cosmetics industries, provide new product solutions, and add new value to their products.